A study found that patients with early hormone-receptor (HR) positive/HER2 negative breast cancer had a significant advantage in invasive disease-free survival when ribociclib, a targeted therapy medicine, was added to hormone treatment.
A study discovered that when ribociclib, a targeted therapy medicine, is added to hormone treatment, patients with early hormone-receptor (HR) positive/HER2 negative breast cancer had a substantial invasive disease-free survival advantage.